78 related articles for article (PubMed ID: 37481795)
1. Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer.
Terán S; Alva M; Tolosa P; Rey-Cárdenas M; Madariaga A; Lema L; Ruano Y; Manso L; Ciruelos E; Sánchez-Bayona R
Breast; 2023 Oct; 71():42-46. PubMed ID: 37481795
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.
Hurson AN; Hamilton AM; Olsson LT; Kirk EL; Sherman ME; Calhoun BC; Geradts J; Troester MA
Breast Cancer Res Treat; 2023 May; 199(1):147-154. PubMed ID: 36892725
[TBL] [Abstract][Full Text] [Related]
3. Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer.
Lien TG; Ohnstad HO; Lingjærde OC; Vallon-Christersson J; Aaserud M; Sveli MAT; Borg Å; Osbreac OBO; Garred Ø; Borgen E; Naume B; Russnes H; Sørlie T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885228
[TBL] [Abstract][Full Text] [Related]
4. Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer.
Veerla S; Hohmann L; Nacer DF; Vallon-Christersson J; Staaf J
NPJ Breast Cancer; 2023 Oct; 9(1):83. PubMed ID: 37857634
[TBL] [Abstract][Full Text] [Related]
5. The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression.
Zhao Y; Chen X; Wang Y; Zhang X; Lu J; Yin W
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610617
[No Abstract] [Full Text] [Related]
6. Impact of HER2-Low status in metastatic gastric cancer:A real-world retrospective cohort study.
Unal OU; Akay S; Gul G; Keser M; Ozamrak BG; Solakoglu Kahraman D; Erdogan M
Oncology; 2024 Feb; ():. PubMed ID: 38354717
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality.
Gámez-Casado S; Rodríguez-Pérez L; Bandera-López C; Mesas-Ruiz A; Campini-Bermejo A; Bernal-Gómez M; Zalabardo-Aguilar M; Calvete-Candenas J; Martínez-Bernal G; Atienza-Cuevas L; García-Rojo M; Benítez-Rodríguez E; Pajares-Hachero B; Bermejo-Pérez MJ; Baena-Cañada JM
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539421
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study.
Yang M; Sun J; Liu L; Kong X; Lin D; Zhou H; Gao J
Sci Rep; 2023 Jul; 13(1):12382. PubMed ID: 37524746
[TBL] [Abstract][Full Text] [Related]
9. Brain metastasis in de novo stage IV breast cancer.
He Y; Shao Y; Chen Q; Liu C; Zhu F; Liu H
Breast; 2023 Oct; 71():54-59. PubMed ID: 37499376
[TBL] [Abstract][Full Text] [Related]
10. Aesthetic results were more satisfactory after oncoplastic surgery than after total breast reconstruction according to patients and surgeons.
Araújo Pereira Lisboa FC; Paulinelli RR; Campos Veras LP; Jubé Ribeiro LF; Pádua Oliveira LF; Sousa Rahal RM; Sousa AG; Freitas-Júnior R; Batista de Sousa J
Breast; 2023 Oct; 71():47-53. PubMed ID: 37487426
[TBL] [Abstract][Full Text] [Related]
11. Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy.
Chen W; Li FX; Lu DL; Jiang J; Li J
Breast; 2023 Oct; 71():69-73. PubMed ID: 37517155
[TBL] [Abstract][Full Text] [Related]
12. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
[TBL] [Abstract][Full Text] [Related]
13. "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?".
Höller A; Nguyen-Sträuli BD; Frauchiger-Heuer H; Ring A
Breast Cancer (Dove Med Press); 2023; 15():525-540. PubMed ID: 37533589
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Nordenskjöld A; Fohlin H; Rosell J; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström P; Rydén L; Wallgren A; Stål O; Nordenskjöld B
Breast; 2023 Oct; 71():63-68. PubMed ID: 37517154
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
16. The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review.
Poelhekken K; Lin Y; Greuter MJW; van der Vegt B; Dorrius M; de Bock GH
Breast; 2023 Oct; 71():74-81. PubMed ID: 37541171
[TBL] [Abstract][Full Text] [Related]
17. Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib.
Sharaf B; Abu-Fares H; Tamimi F; Al-Sawajneh S; Salama O; Daoud R; Alhajahjeh A; Al-Lababidi S; Abdel-Razeq H
Breast Cancer (Dove Med Press); 2023; 15():541-548. PubMed ID: 37533590
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
Tarantino P; Tolaney SM; Curigliano G
Ann Oncol; 2023 Oct; 34(10):949-950. PubMed ID: 37499870
[No Abstract] [Full Text] [Related]
19. The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
Wei T; Wang D; Yuan P
Ann Oncol; 2023 Oct; 34(10):948-949. PubMed ID: 37499869
[No Abstract] [Full Text] [Related]
20. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
